Pharmacoeconomic review report Lixisenatide (Adlyxine) (Sanofi-aventis Canada Inc.)
Lixisenatide (Adlyxine) is a glucagon-like peptide-1 receptor agonist indicated for the treatment of type 2 diabetes mellitus in patients uncontrolled on basal insulin with or without oral glucose-lowering agents. The starting dose is 10 mcg once daily for 14 days, then increased to 20 mcg once dail...
| Autor principal: | |
|---|---|
| Autor Corporativo: | |
| Formato: | Libro electrónico |
| Idioma: | Inglés |
| Publicado: |
Ottawa (ON) :
Canadian Agency for Drugs and Technologies in Health
2017.
|
| Materias: | |
| Ver en Biblioteca Universitat Ramon Llull: | https://discovery.url.edu/permalink/34CSUC_URL/1im36ta/alma991009820269306719 |
Tabla de Contenidos:
- Abbreviations
- Executive Summary
- Background
- Summary of Identified Limitations and Key Results
- Conclusions
- Information on the Pharmacoeconomic Submission
- Summary of the Manufacturer's Pharmacoeconomic Submission
- Manufacturer's Base Case
- Summary of Manufacturer's Sensitivity Analyses
- Limitations of Manufacturer's Submission
- CADTH Common Drug Review Re-Analyses
- Issues for Consideration
- Patient Input
- Conclusions
- Appendix 1. Cost Comparison
- Appendix 2. Summary of Key Outcomes
- Appendix 3. Additional Information
- Appendix 4. Summary of Other CADTH Health Technology Assessment Reviews
- Appendix 5. Reviewer Worksheets
- References.
